articleTop 1% cited

Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients

Clinical Cancer Research · 2009 · Vol. 15(6) · pp. 2148–2157

Jennifer S. Ko✉(Cancer Institute (WIA))Arnold H. Zea(Louisiana State University Health Sciences Center New Orleans)Brian I. Rini(Case Comprehensive Cancer Center)Joanna Ireland(Cleveland Clinic Lerner College of Medicine)Paul Elson(Cleveland Clinic)Peter A. Cohen(Cleveland Clinic Lerner College of Medicine)Ali Golshayan(Cancer Institute (WIA))Patricia Rayman(Cleveland Clinic Lerner College of Medicine)Laura S. Wood(Cancer Institute (WIA))Jorge A. García(Case Comprehensive Cancer Center)Robert Dreicer(Cleveland Clinic)Ronald M. Bukowski(Cancer Institute (WIA))James H. Finke(Cancer Institute (WIA))

View via DOI Publisher page

Abstract

Sunitinib-based therapy has the potential to modulate antitumor immunity by reversing MDSC-mediated tumor-induced immunosuppression.

Immune cells in cancer Cancer Immunotherapy and Biomarkers Histone Deacetylase Inhibitors ResearchSunitinibMyeloid-derived Suppressor CellMedicineCancer researchT cellRenal cell carcinomaImmune systemTyrosine-kinase inhibitorPharmacologyImmunology

MeSH terms

SunitinibAdultAgedAged, 80 and overAntineoplastic AgentsCarcinoma, Renal CellFemaleHumansIndolesInterferon-gammaKidney NeoplasmsMaleMiddle AgedPyrrolesSuppressor Factors, Immunologic

Citations

852

FWCI

22.84

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

AACR Centennial Series: The Biology of Cancer Metastasis: Historical Perspective